Pfizer announced that they have seen success in the early stages of human trials for a coronavirus vaccine. The trial included 45 people who were randomly given either a 10, 30, or 100 microgram dose of the vaccine or a placebo. Those who received the 10 and 30 microgram doses were given two injections, while those who got the larger dose only got one. The booster shot was given three weeks after the first treatment.
After 28 days, the patients who received the smaller doses developed more COVID-19 antibodies than patients who had previously recovered from the viral infection.
Some of the patients did suffer minor side effects, including fever and pain at the injection site.
Based on the promising results of the early trial, Pfizer hopes to begin a larger test involving around 30,000 people later this month.
If the vaccine proves effective, the pharmaceutical company said they could manufacture 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021.
"We are dedicated to developing potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency," Kathrin Jansen, head of Pfizer's vaccine research and development, said in a press release.
Photo: Getty Images